17-α Hydroxyprogesterone Nanoemulsifying Preconcentrate-Loaded Vaginal Tablet: A Novel Non-Invasive Approach for the Prevention of Preterm Birth
Open Access
- 14 July 2019
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (7) , 335
Abstract
Preterm birth (PTB) is a major cause of infant mortality in the United States and around the globe. Makena®—once-a-week intramuscular injection of 17-α Hydroxyprogesterone caproate (17P)—is the only FDA approved treatment for the prevention of PTB. Invasive delivery of 17P requires hospitalization and expert personnel for injection. Vaginal delivery of 17P would be preferable, because of high patient compliance, reduced systemic exposure, fewer side effects, and no need for hospitalization. The objective of the present study was to prepare and evaluate a self-nanoemulsifying vaginal tablet of 17P. A solid self-nanoemulsifying preconcentrate (S-SNEDDS) of 17P and dimethylacetamide (DMA) was developed using medium chain triglycerides, a non- immunogenic surfactant, and co-processed excipient (PVA-F100). The tablet prepared was characterized for emulsification time, particle size, solid state properties, and drug release. The formulation showed >50% inhibition of TNF-α release from LPS-stimulated RAW 264.7 cells. Importantly, there were significant differences in rates of PTB and average time to delivery between control and vaginal 17P-treated groups in LPS-stimulated timed pregnant E15.5 mice. Considering the lacuna of therapeutic approaches in this area, vaginal delivery of 17P for the prevention of preterm birth has significant clinical relevance.Keywords
This publication has 49 references indexed in Scilit:
- Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birthPatient Preference and Adherence, 2013
- Potential Risks of Pharmacy CompoundingDrugs in R&D, 2013
- Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injectionDrug Development and Industrial Pharmacy, 2011
- Racial/ethnic disparities in preterm birth: clues from environmental exposuresCurrent Opinion in Pediatrics, 2011
- The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidityBulletin of the World Health Organization, 2010
- The preterm parturition syndrome and its implications for understanding the biology, risk assessment, diagnosis, treatment and prevention of preterm birthThe Journal of Maternal-Fetal & Neonatal Medicine, 2009
- Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone CaproateNew England Journal of Medicine, 2003
- New Hypotheses. Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterusHuman Reproduction Update, 1999
- Determination of progesterone and 17-hydroxyprogesterone by high performance liquid chromatography after pre-column derivatization with 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a- diaza-s-indacene-3-propionohydrazideThe Analyst, 1998
- The First Uterine Pass EffectAnnals of the New York Academy of Sciences, 1997